Tirzepatide shows a gynaecological tumour signal in pooled trial data

GLP-1 receptor agonists and SGLT2 inhibitors have become some of the most widely used drug classes in metabolic medicine, and questions about their long-term safety carry real weight. Concerns have emerged about oncogenic potential, particularly in relation to gynaecologic malignancies, yet no consensus existed on whether risk differs between specific drugs and doses. Because these medicines are frequently prescribed to people who already carry predisposing risk factors, an honest accounting of any tumour signal in the trial record matters to the many women taking them. This analysis set out to compare gynaecologic tumour incidence across individual regimens.

The researchers ran a network meta-analysis, a method that compares many treatments across trials even when those treatments were never tested head to head, following a Cochrane-recommended confirmatory approach. They systematically searched major databases up to 3 March 2025 for randomised controlled trials including female participants. Ninety-one trials comprising 224,986 participants, of whom 89,558 were women, were included. The primary outcome was the incidence of gynaecologic tumours, drop-out rates served as an acceptability measure, and Bayesian sensitivity analyses were run to check that the findings held.

Only high-dose tirzepatide at 15mg per week was associated with a significantly increased overall gynaecologic tumour risk compared with controls, with odds 2.37 times higher, an absolute risk difference of 0.57%, and a number needed to harm of 176. In site-specific analysis, both the 15mg and 5mg weekly doses of tirzepatide were associated with elevated risk of intra-uterine tumours, with odds ratios of 4.65 and 4.61 respectively, though both estimates carried wide uncertainty. No other GLP-1 or SGLT2 regimen showed a significant elevation in risk.

This appears to be the first regimen-specific comparison of gynaecologic tumour risk across these two drug classes, and its most reassuring finding is the absence of a signal for every regimen except tirzepatide. The authors are explicit that the tirzepatide association may still reflect chance or bias rather than causation, and that longitudinal research is needed to clarify mechanisms and guide clinical decisions. The wide statistical uncertainty around the estimates means the true size of any risk is far from settled. The finding is best read as a flag for further study, not an established danger.

For anyone taking or considering tirzepatide, the honest reading is a small and unconfirmed signal: the absolute risk difference was 0.57%, and the authors call for more data before drawing causal conclusions. It is also worth registering what did not show a signal, namely every other GLP-1 and SGLT2 regimen examined. Knowing this analysis exists is a reason to watch for future safety updates and to raise the question with a prescriber if it concerns you, rather than a reason to change anything on your own.